Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed With Epilepsy

NCT07238868 is registered in ClinicalTrials.gov with Shanghai Zhimeng Biopharma, Inc. as lead sponsor.

NCT NCT07238868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07238868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed With Epilepsy
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 14, 2025
Completion date
June 30, 2029
Enrollment
144 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

focal epilepsy